Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seviteronel in mCRPC and Advanced Breast Cancer
NCT02130700Phase 2Completed
- Sponsor
- Innocrin
- Start
- Apr 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of seviteronel in metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer (TNBC), estrogen receptor-positive breast cancer (ER+), sponsored by Innocrin. Started Apr 2014; status: completed.
02
Drugs
seviteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)triple-negative breast cancer (TNBC)estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02130700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130700.